Nkarta reports full year 2021 net loss of $86.1M; NKX101 data expected 1H 2022

Nkarta, Inc.

Full year 2021 net loss $86.1M ($2.62/share); Q4 net loss $22.8M ($0.69/share).
Cash and investments $240.2M as of Dec 31, 2021; cash runway into 2H 2023.
R&D expenses $63.4M full year; G&A $23.0M; non-cash stock-based comp $14.5M.
NKX101 Phase 1 monotherapy data (AML/MDS) expected 1H 2022; NKX019 data in 2022.
NKX101 received FDA orphan drug designation for AML; protocol amendments filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.